The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor γ gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers

Clinical Science

Volumn 107, Issue 5, 2004, Pages 461-466

  Chao, Ting Hsing ^a   Li, Yi Heng ^a   Chen, Jyh Hong ^a   Wu, Hua Lin ^a   Shi, Guey Yueh ^a   Liu, Ping Yen ^a   Tsai, Wei Chuan ^a   Guo, How Ran ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Acute myocardial infarction; Atherosclerosis; Oxidized low density lipoprotein; Peroxisome proliferator activated receptor (PPAR); Polymorphism; Smoking

Indexed keywords

CELL NUCLEUS RECEPTOR; LIGAND; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ACUTE HEART INFARCTION; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SMOKING;

ADULT; AGE OF ONSET; AUTOANTIBODIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PPAR GAMMA; RISK FACTORS; SMOKING;

EID: 8644275374     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20040014     Document Type: Article

References (50)

1. Ross, R. and Glomset, J. A. (1973) Atherosclerosis and the arterial smooth muscle cell. Science (Washington, D.C.) 180, 1332
2. Ross, R. and Glomset, J. A. (1976) The pathogenesis of atherosclerosis. N. Engl. J. Med. 295, 369-377
3. Ross, R. and Harker, L. (1976) Hyperlipidemia and atherosclerosis. Science (Washington, D.C.) 193, 1094
4. DeWood, M. A., Spores, J. and Notske, R. N. (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med. 303, 897-902
5. Ridolfi, R. L. and Hutchins, G. M. (1977) The relationship between coronary arterial lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis. Am. Heart J. 93, 468-486
6. Fuster, V., Badimon, L., Badimon, J. J. and Chesebro, J. H. (1992) Mechanisms of disease: the pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326, 242-250
7. Miletich, J. P., Prescott, S. M., White, R., Majerus, P. W. and Bovill, E. G. (1993) Inherited predisposition of thrombosis. Cell (Cambridge, Mass.) 72, 477-480
8. Siscovick, D. S., Schwartz, S. M., Rosendaal, F. R. and Psaty, B. M. (1997) Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb. Haemostasis 78, 7-12
9. Franco, R. F. and Reitsma, P. H. (2001) Gene polymorphisms of the haemostatic system and the risk of arterial tnrombotic disease. Br. J. Haematol. 115, 491-506
10. Merlini, P. A. and Ardissino, D. (2001) Genetic polymorphisms to evaluate the risk of myocardial infarction: a long way away. Thromb. Haemostasis 86, 1136-1138
11. Lemberger, T., Desvergne, B. and Wahli, W. (1996) Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu. Rev. Cell Dev. Biol. 12, 335-363
12. Chao, L., Marcus-Samuels, B., Mason, M. M. et al. (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106, 1221-1228
13. Santomauro, A. T., Boden, G., Silva, M. E. et al. (1999) Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48, 1836-1841
14. Raskin, P., Rappaport, E. B., Cole, S. T., Yan, Y., Patwardhan, R. and Freed, M. I. (2000) Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43, 278-284
15. Wolffenbuttel, B. H. R., Gomis, R., Squatrito, S., Jones, N. P. and Patwardhan, R. N. (2000) Addition of low dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet. Med. 17, 40-47
16. Parulkar, A. A., Pendergrass, M. L., Granda-Ayala, R., Lee, T. R. and Fonseca, V. A. (2001) Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 134, 61-71
17. Cominacini, L., Garbin, U., Fratta, P. A. et al. (1998) Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 47, 130-133
18. Ehrmann, D. A., Schneider, D. J., Sobel, B. E. et al. (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82, 2108-2116
19. Fonseca, V. A., Reynolds, T., Hemphill, D. et al. (1998) Effect of troglitazone of fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J. Diabet. Complications 12, 181-186
20. Nordt, T. K., Peter, K., Bode, C. and Sobel, B. E. (2000) Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J. Clin. Endocrinol. Metab. 85, 1563-1568
21. Ishizuka, T., Itaya, S., Wada, H. et al. (1998) Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone human platelet aggregation mechanisms. Diabetes 47, 1494-1500
22. Law, R. E., Meehan, W. P., Xi, X. P. et al. (1996) Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98, 1897-1905
23. Minamikawa, J., Tanaka, S., Yamauchi, M., Inoue, D. and Koshiyama, H. (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 83, 1818-1820
24. Jiang, C., Ting, A. T. and Seed, B. (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature (London) 391, 82-86
25. Haffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K. and Freed, M. I. (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106, 679-684
26. Marx, N., Froehlich, J., Siam, L. et al. (2003) Antidiabetic PPAR γ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler., Thromb., Vasc. Biol. 23, 283-288
27. Garg, R., Kumbkarni, Y., Aljada, A. et al. (2000) Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 36, 430-435
28. Wang, X. L., Oosterhof, J. and Duarte, N. (1999) Peroxisome proliferator-activated receptor γ C161 → T polymorphism and coronary artery disease. Cardiovasc. Res. 44, 588-594
29. Meirhaeghe, A., Fajas, L., Helbecque, N. et al. (1998) A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Hum. Mol. Genet. 7, 435-440
30. Loffreda, S., Yang, S. Q., Lin, H. Z. et al. (1998) Leptin regulates proinflammatory immune responses. FASEB. J. 12, 57-65
31. Faggioni, R., Fantuzzi, G., Fuller, J., Dinarello, C. A., Feingold, K. R. and Grunfeld, C. (1998) IL-1 beta mediates leptin induction during inflammation. Am. J. Physiol. 274, R204-R208
32. Fantuzzi, G. and Faggioni, R. (2000) Leptin in the regulation of immunity, inflammation, and hematopoiesis. J. Leukocyte Biol. 68, 437-446
33. Soderberg, S., Ahren, B., Jansson, J. H. et al. (1999) Leptin is associated with increased risk of myocardial infarction. J. Intern. Med. 246, 409-418
34. Meisel, S. R., Ellis, M., Pariente, C. et al. (2001) Serum leptin levels increase following acute myocardial infarction. Cardiology 95, 206-211
35. Tsai, W. C., Li, Y. H., Chao, T. H. and Chen, J. H. (2002) Relation between antibody against oxidized low-density lipoprotein and extent of coronary atherosclerosis. J. Formos. Med. Assoc. 101, 681-684
36. Ireland, H., Kunz, G., Kyriakoulis, K., Stubbs, P. J. and Lane, D. A. (1997) Thrombomodulin gene mutations associated with myocardial infarction. Circulation 96, 15-18
37. Le Flem, L., Picard, V., Emmerich, J. et al. (1999) Mutations in promoter region of thrombomodulin and venous thromboembolic disease. Arterioscler., Thromb., Vasc. Biol. 19, 1098-1104
38. Li, Y. H., Chen, J. H., Tsai, W. C. et al. (2002) Synergic effect of thrombomodulin promoter -33G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb. Haemostasis 87, 86-91
39. Park, H. Y., Jang, Y., Kim, Y., Shim, W. H. and Kwon, H. M. (2000) Common genetic variants of the thrombomodulin gene as a risk factor for myocardial infarction. J. Am. Coll. Cardiol. 35, 327A
40. Koide, S. I., Kugiyama, K., Sugiyama, S. et al. (2003) Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with coronary vasomotor dysfunction and myocardial infarction. J. Am. Coll. Cardiol. 41, 539-545
41. Witztum, J. L. and Steinberg, D. (1991) Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88, 1785-1792
42. Palinski, W., Ylä-Herttuala, S., Rosenfeld, M. E. et al. (1990) Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10, 325-335
43. Inoue, T., Uchida, T., Kamishirado, H., Takayanagi, K., Hayashi, T. and Morooka, S. (2001) Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J. Am. Coll. Cardiol. 37, 775-779
44. Puurunen, M., Manttari, M., Manninen, V. et al. (1994) Antibody against oxidized low-density lipoprotein in predicting myocardial infarction. Arch. Intern. Med. 154, 2605-2609
45. Teng, J. K., Lin, L. J., Tsai, L. M., Kwan, C. M. and Chen, J. H. (1994) Acute myocardial infarction in young and very old Chinese adults: clinical and therapeutic implications. Int. J. Cardiol. 44, 29-36
46. Marx, N., Schonbeck, U., Lazar, M. A., Libby, P. and Plutzky, J. (1998) Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83, 1097-1103
47. Ricote, M., Li, A. C., Wilson, T. M., Kelly, C. J. and Glass, C. K. (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (London) 391, 79-82
48. Plutzky, J. (2001) Inflammatory pathway in atherosclerosis and acute coronary syndrome. Am. J. Cardiol. 88, 10K-15K
49. Mulvihill, N. T. and Foley, J. B. (2002) Inflammation in acute coronary syndrome. Heart 87, 201-204
50. Bluher, M., Klem, T., Gerike, T., Krankergerg, H., Schuler, G. and Paschke, R. (2002) Lack of association between PPAR γ gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus. Eur. J. Endocrinol. 146, 545-551